Clearmind Medicine granted patent for binge behavior treatment by Macau

Clearmind Medicine (CMND) announces advancement in its proprietary MEAI- based binge behavior regulator program through the granting of patent approval from the Macau International Intellectual Property Office. The allowed patent is directed, among others to be used as primary amine aminoindan compound to regulate binge behavior. This includes primary amine aminoindan compounds beyond 5-methoxy-2-aminoindan, the Company’s innovative psychedelic molecule. This latest granted patent in Macau, a special administrative region of China, strengthens Clearmind’s global intellectual property portfolio, which now includes 31 granted patents across 18 patent families.